Alembic Pharma Gets USFDA Nod for Oseltamivir Oral Suspension

VADODARA — Alembic Pharmaceuticals Limited announced on Friday, June 26, 2026, that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oseltamivir Phosphate for Oral Suspension, 6 mg/mL. This regulatory milestone marks the company's continued expansion in the North American generic drug market.

The approved oral suspension is the therapeutic equivalent of the reference listed drug (RLD), Tamiflu Oral Suspension, 6 mg/mL, marketed by Hoffmann-La Roche, Inc. Oseltamivir Phosphate is an influenza neuraminidase inhibitor (NAI) used for the treatment of acute, uncomplicated influenza A and B in patients two weeks of age and older, and for the prophylaxis of the virus in patients one year and older.

Strategic Portfolio Expansion

This latest approval strengthens Alembic's respiratory and generic portfolio in the United States. According to data from the healthcare analytics firm IQVIA, the Oseltamivir Phosphate oral suspension market in the U.S. had an estimated market size of US$ 27 million for the twelve months ending March 2026.

Alembic Pharmaceuticals, headquartered in India, has seen a consistent trajectory in its USFDA engagement. Following this approval, the company now holds a cumulative total of 243 ANDA approvals, comprising 223 final approvals and 20 tentative approvals.

Regulatory Context and Market Impact

The final approval for Oseltamivir Phosphate follows a flurry of regulatory activity for Alembic throughout June 2026. Earlier this month, the company secured final approval for Tretinoin Cream USP, 0.05%—a generic version of Retin-A—and received tentative approvals for oncology products, including Larotrectinib capsules and Binimetinib tablets.

These successive approvals underscore Alembic’s focus on diversifying its U.S. presence across various therapeutic classes, ranging from dermatology and respiratory health to complex oncology treatments. By targeting both high-volume generic segments and specialized oncology molecules, the company aims to optimize its revenue mix in the world’s largest pharmaceutical market.

Official Sources

According to the company’s regulatory filing submitted to the National Stock Exchange (NSE) on June 26, 2026, the approval follows the successful submission of the ANDA, which met all safety and efficacy standards required by the USFDA for therapeutic equivalence.

"Alembic Pharmaceuticals Limited today announced that it has received final approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Oseltamivir Phosphate for Oral Suspension, 6 mg/mL," the company stated in its official press release.

Why It Matters

For the healthcare sector and patients in the U.S., the introduction of generic Oseltamivir Phosphate can lead to increased access and reduced costs for essential influenza treatments. For investors, the steady stream of USFDA approvals serves as an indicator of Alembic’s manufacturing capability and its ongoing commitment to leveraging its research and development facilities to maintain competitive positioning in regulated international markets.

Key Facts at a Glance

• Product: Oseltamivir Phosphate for Oral Suspension, 6 mg/mL.

• Approval Type: Final USFDA approval for the ANDA.

• Reference Drug: Therapeutically equivalent to Tamiflu Oral Suspension by Hoffmann-La Roche, Inc.

• Market Size: Estimated US$ 27 million for the 12 months ending March 2026.

• Company Portfolio: Total cumulative ANDA approvals now stand at 243.

Frequently Asked Questions (FAQ)

1. What is Oseltamivir Phosphate used for? It is an antiviral medication indicated for the treatment of acute, uncomplicated influenza A and B in patients aged two weeks and older, and for preventing (prophylaxis) the virus in patients one year and older.

2. How many USFDA approvals does Alembic currently hold? As of June 26, 2026, Alembic Pharmaceuticals has a cumulative total of 243 ANDA approvals (223 final and 20 tentative).

3. What does "therapeutic equivalence" mean in this context? It means the FDA has determined that Alembic’s generic version is equivalent to the brand-name drug (Tamiflu) in dosage form, strength, route of administration, quality, and performance characteristics.

4. When will the product be available for sale? The final approval allows Alembic to immediately proceed with commercialization in the U.S. market, subject to the company's internal launch timelines.

Source: Alembic Pharmaceuticals Limited Press Release, U.S. Food and Drug Administration (USFDA)